Timolol 0.5% Ophthalmic Solution

University of California, Davis · FDA-approved active Small molecule

Timolol 0.5% Ophthalmic Solution is a Beta-adrenergic antagonist Small molecule drug developed by University of California, Davis. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension. Also known as: timoptic, Timoptol, TIMOLOL.

Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.

Timolol 0.5% Ophthalmic Solution is a small molecule that acts as a beta-1 adrenergic receptor antagonist. It is used to treat conditions such as Primary Open-Angle Glaucoma, Ocular Hypertension, and Suspect Glaucoma.

At a glance

Generic name	Timolol 0.5% Ophthalmic Solution
Also known as	timoptic, Timoptol, TIMOLOL
Sponsor	University of California, Davis
Drug class	Beta-adrenergic antagonist
Target	Beta-1 and beta-2 adrenergic receptors
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	FDA-approved

Mechanism of action

Timolol blocks beta-1 and beta-2 adrenergic receptors on the ciliary body epithelium, which reduces the rate of aqueous humor secretion. This leads to a decrease in intraocular pressure, making it effective for treating glaucoma and ocular hypertension. The ophthalmic solution formulation allows direct topical application to the eye for local therapeutic effect.

Approved indications

• Open-angle glaucoma
• Ocular hypertension

Common side effects

• Ocular irritation or discomfort
• Blurred vision
• Conjunctival hyperemia
• Systemic beta-blockade effects (bradycardia, bronchospasm in susceptible patients)

Key clinical trials

• Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
• Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris (EARLY_PHASE1)
• Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas (PHASE4)
• Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
• Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE2, PHASE3)
• Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) (PHASE2)
• Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing (PHASE2)
• Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Timolol 0.5% Ophthalmic Solution CI brief — competitive landscape report
• Timolol 0.5% Ophthalmic Solution updates RSS · CI watch RSS
• University of California, Davis portfolio CI

Frequently asked questions about Timolol 0.5% Ophthalmic Solution

What is Timolol 0.5% Ophthalmic Solution?

Timolol 0.5% Ophthalmic Solution is a Beta-adrenergic antagonist drug developed by University of California, Davis, indicated for Open-angle glaucoma, Ocular hypertension.

How does Timolol 0.5% Ophthalmic Solution work?

Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.

What is Timolol 0.5% Ophthalmic Solution used for?

Timolol 0.5% Ophthalmic Solution is indicated for Open-angle glaucoma, Ocular hypertension.

Who makes Timolol 0.5% Ophthalmic Solution?

Timolol 0.5% Ophthalmic Solution is developed and marketed by University of California, Davis (see full University of California, Davis pipeline at /company/university-of-california-davis).

Is Timolol 0.5% Ophthalmic Solution also known as anything else?

Timolol 0.5% Ophthalmic Solution is also known as timoptic, Timoptol, TIMOLOL.

What drug class is Timolol 0.5% Ophthalmic Solution in?

Timolol 0.5% Ophthalmic Solution belongs to the Beta-adrenergic antagonist class. See all Beta-adrenergic antagonist drugs at /class/beta-adrenergic-antagonist.

What development phase is Timolol 0.5% Ophthalmic Solution in?

Timolol 0.5% Ophthalmic Solution is FDA-approved (marketed).

What are the side effects of Timolol 0.5% Ophthalmic Solution?

Common side effects of Timolol 0.5% Ophthalmic Solution include Ocular irritation or discomfort, Blurred vision, Conjunctival hyperemia, Systemic beta-blockade effects (bradycardia, bronchospasm in susceptible patients).

What does Timolol 0.5% Ophthalmic Solution target?

Timolol 0.5% Ophthalmic Solution targets Beta-1 and beta-2 adrenergic receptors and is a Beta-adrenergic antagonist.

Related

• Drug class: All Beta-adrenergic antagonist drugs
• Target: All drugs targeting Beta-1 and beta-2 adrenergic receptors
• Manufacturer: University of California, Davis — full pipeline
• Therapeutic area: All drugs in Ophthalmology
• Indication: Drugs for Open-angle glaucoma
• Indication: Drugs for Ocular hypertension
• Also known as: timoptic, Timoptol, TIMOLOL